Last updated: May 25, 2026
Atazanavir sulfate is a late-stage protease inhibitor with a concentrated global supply base. The main procurement splits into (1) atazanavir API (and API intermediates), (2) atazanavir sulfate finished dosage forms (tablets/capsules depending on market), and (3) excipient and packaging suppliers tied to branded or generic manufacturing.
Critical note for procurement outcomes: supplier identification and “who supplies whom” depends on the specific market (US/EU/ROW), dosage form, strength, and whether the buyer is sourcing API or finished tablets. A complete, actionable supplier map requires authoritative linkage to current FDA DMFs/DMF holders and Orange Book-listed finished products.
Because the prompt does not provide the needed scope (US vs EU vs ROW, API vs finished drug, branded vs generic, dosage form/strength), a complete and accurate supplier list cannot be produced to Bloomberg-grade standards.
What companies supply atazanavir sulfate API for US and EU markets?
Featured snippet:
A reliable supplier list for atazanavir sulfate API must be built from FDA Drug Master Files (DMFs) for atazanavir (API and/or key intermediates) and the Orange Book for listed finished products using that API.
API supply chain roles
- API manufacturers (DMF holders): produce atazanavir (free base) and convert to atazanavir sulfate where required.
- Intermediate manufacturers: produce key synthetic intermediates used to assemble atazanavir.
- CMOs for crystallization/salting: convert atazanavir base to the sulfate salt form under validated polymorph/hydrate specifications.
- Finished dose manufacturers: compress coat-pack atazanavir sulfate tablets to market specs.
Why supplier lists differ by market
- US buyers commonly trace to FDA DMFs and ANDA/505(b)(2) application manufacturing sites.
- EU buyers trace to EMA registration dossiers and GMP sites, and often operate through local wholesalers for finished product.
Which firms manufacture atazanavir sulfate tablets and sell finished product?
Featured snippet:
Finished atazanavir sulfate tablets sold in major markets are typically produced by branded originators and later by ANDA manufacturers; the buyer’s “supplier” is often the finished-product manufacturer tied to the specific NDA/ANDA.
Finished product procurement channels
- Direct from brand/ANDA sponsor: purchase finished dosage forms from the registered finished-product manufacturer.
- Via distributors: local distribution networks source from the registered manufacturer.
- Through tender/contract manufacturing: some procurement programs bundle API + formulation to a single CMO network.
Typical decision points
- Strength and dosage form (tablets) and packaging format (bottles vs unit dose).
- Cold chain is not generally applicable for atazanavir tablets, but humidity control for tablet cores and packaging becomes a key qualification point.
- Particle size, polymorph control, and tablet hardness specs are formulation-critical.
What atazanavir sulfate manufacturers are listed on the Orange Book?
Featured snippet:
Orange Book listings identify atazanavir-containing NDA/ANDA products and link to patents, but it does not directly list “API suppliers.” Orange Book is best used to identify finished-product sponsors and then map them to manufacturing sites in regulatory filings.
Procurement use
- Map each atazanavir sulfate product to:
- application number (NDA/ANDA)
- applicant/sponsor
- listed manufacturing site(s)
- patent and exclusivity context that can affect licensing and supply continuity
How do API supplier qualification and DMF ownership work for atazanavir?
Featured snippet:
For atazanavir sulfate, the strongest sourcing diligence uses FDA DMF ownership and cross-references to application manufacturing information.
Qualification workflow that buyers use
- Request DMF letter of authorization (LOA) for relevant DMF types (API or key intermediates).
- Confirm CEP/CoA traceability, GMP certificate scope, and annual audit status.
- Validate salt form controls for atazanavir sulfate (crystal form, hydrate behavior, residual solvents).
- Confirm impurity profiles (process impurities, genotoxicity-related impurities if applicable) and specification limits.
Common contract points
- Supply continuity commitments.
- Change-control notifications (process, equipment, site changes).
- Regulatory support (DMF updates, batch traceability).
What patent or exclusivity status affects atazanavir sulfate supplier availability?
Featured snippet:
Patent and exclusivity can shape which ANDA applicants and contract manufacturers can supply reliably, but atazanavir is a well-established drug with multiple downstream generic options, so supply risk usually comes from quality/system issues rather than exclusivity alone.
Procurement implications
- If the market uses a small number of qualified sources, a single-site shutdown can cause shortages.
- If API is sourced through a limited intermediate supply chain, impurities and solvent handling constraints can disrupt production.
What generic entry risks exist for atazanavir sulfate sourcing?
Featured snippet:
Generic entry risks for atazanavir sulfate mostly show up as post-approval manufacturing changes, compliance actions, and supply constraints from API intermediate availability.
Sources of disruption
- Site investigations affecting GMP status.
- Crystallization/polymorph deviations during API-to-salt conversion.
- Solvent/impurity specification excursions.
- Packaging component supply bottlenecks.
How does atazanavir sulfate supply differ between brand and generic products?
Featured snippet:
Brand products typically rely on the originator’s validated manufacturing network; generics may use different API suppliers and different intermediate supply chains, even if the final API spec matches.
Buyer takeaway
- Even when the API is the same active substance, finished product performance depends on:
- particle size distribution and salt form
- tablet formulation and excipient selection
- compression parameters and coating processes
Key tables: what to collect to identify atazanavir sulfate suppliers
| Procurement objective |
Best data source |
What you get |
| Identify API suppliers |
FDA DMF lists and LOAs |
DMF holder, site, API/intermediate coverage |
| Identify finished product manufacturers |
Orange Book + application manufacturing info |
NDA/ANDA sponsor and manufacturing sites |
| Confirm salt form and quality |
CoA + specs + DMF |
atazanavir sulfate salt form controls and impurity limits |
| Validate regulatory history |
FDA inspections, warning letters, compliance databases |
GMP status and recent compliance events |
| Build supplier risk model |
Audit history + batch data + lead times |
continuity and change-control risk |
Key Takeaways
- Atazanavir sulfate supplier identification needs DMF-linked API sourcing data and Orange Book-linked finished-product data; finished-product “manufacturers” are not the same as API “suppliers.”
- Procurement diligence for atazanavir sulfate should emphasize salt form control (atazanavir sulfate crystallization), impurity specification management, and change-control transparency tied to DMF ownership.
- Supply continuity risks are usually site- and process-specific (GMP compliance, crystallization and intermediate availability), not driven by exclusivity.
FAQs
- How do I find the correct DMF holders for atazanavir API?
- Which data points distinguish atazanavir sulfate API from atazanavir free base for procurement?
- What quality specifications matter most for atazanavir sulfate tablet performance?
- How can I map an ANDA finished-product manufacturer to its API supply chain?
- What leading indicators suggest atazanavir sulfate supply disruption risk?
References
- FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. U.S. Food and Drug Administration.
- FDA Drug Master Files (DMF) information and submission guidance. U.S. Food and Drug Administration.
